Celltrion has acquired exclusive global development and commercialisation rights to Kaigene's investigational monoclonal antibody, KG013, in a deal worth up to $580m.

Boehringer Ingelheim and Microsoft have entered into a strategic collaboration to examine the use of AI in clinical research, beginning with studies in lung health.

Numerous types of equity deals involving Chinese biotech, including the popular NewCo model, will be impacted by the proposed rule.

AI Proteins and Astellas Innovation Management have signed a research collaboration and licence deal to discover and develop miniprotein therapeutics.

This insitro deal sees AstraZeneca double down on its plans to enter the MASH market, which is expected to reach a value of $20.3bn in 2032.

Following its provisional blessing in IgAN, AstraZeneca's Ultomiris is now indicated for use in six conditions.

Fenwick partners Chelsea Anderson and Noah Solowiejczyk outline how prediction markets will impact how biotechs operate.

At CPHI Milan 2026, pharma leaders examined how AI can accelerate formulation, process development, maintenance, and quality management—without compromising data security or human oversight.

The US FDA has approved Viatris' Ryzumvi (phentolamine ophthalmic solution 0.75%) to treat presbyopia in adults.

Ambrose will now enter the race to debut a new medicine on the HPP market as the only approved therapy edges closer to key patent expiries.

The US Food and Drug Administration (FDA) has rolled out a new framework to spur development of new therapies for rare diseases, marking the latest initiative carried out by the T ...

UK children at risk of anaphylaxis could soon have another treatment option available at school, after the Medicines and Healthcare products Regulatory Agency (MHRA) said it would consider allowing ...